ArticleDiscover oncology2025
Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function.Pakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related death globally, with treatment challenges persisting in locally advanced or inoperable cases. To evaluate the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with chemoradiotherapy and immune drugs in patients with locally advanced non-small cell lung cancer (NSCLC) who could not undergo surgery.
methodsA retrospective analysis was conducted on 190 patients with locally advanced NSCLC who could not undergo surgery. Patients were divided into group A (synchronous chemoradiotherapy combined with Endostar followed by immune consolidation therapy) and group B (synchronous chemoradiotherapy combined with Endostar followed by Endostar maintenance therapy). Treatment included continuous infusion of Endostar during radiotherapy, with a 21-day cycle. Radiotherapy was performed using intensity-modulated radiotherapy with conventional fractionation, delivering a dose of 60-66 Gy/30-33 fractions to the primary tumor and mediastinal lymph nodes over 6-7 weeks. Chemotherapy was platinum-based doublet chemotherapy. The recent efficacy, clinical benefit rate, disease progression time, overall survival time, and adverse reactions were observed.
resultsThe effective rates were 12% and 19.2%, and the disease control rates were 88% and 61.5% in groups A and B, respectively. The median progression-free survival (mPFS) was 29.83 months in group A and 8.73 months in group B, while the median overall survival (mOS) was 50.47 months in group A and 25.67 months in group B. The main adverse reactions in both groups were mostly grades 0-2.
conclusionEndostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.